Omics! Omics!

One of the two big buzzes in the genomics business world was the announcement that Roche Diagnostics has signed a major deal with Pacific Bi...

Over at Homolog.us there are two detailed blog entries on Pacific Biosciences entitled "End of Short Read Era?" ( Part I  and Par...

Kendall Square used to have the ultimate geek book store, Quantum Books.  No fiction or graphic novels there; it was all technical books.  O...

LinkedIn has a feature by which one can endorse other people for different fields. Periodically the system prompts me to vote yea-or-nay on ...

I've been thinking about this piece for a while, because I am a frequent presence on SEQAnswers.com  and often dive into questions regar...

The big sequencing platform news this week is Roche's announcement that they are ending their collaborations aimed at developing new seq...

I've been mulling this item ever since AGBT, but have struggled with the title.  I don't want to sound like I have a grudge against ...

Back-of-the-envelope calculations can be quite useful, but also quite dangerous.  They are meant to be quick estimates, but can't be tak...

As others have noted , a significant theme at AGBT this year was sequencing at length.  While this year lacked true bombshells, PacBio impr...

In the previous post I described the Nabsys positional sequencer. Yesterday I got o see it running in their hotel suite here at AGBT13.

A complaint which seems to be circulating on Twitter and elsewhere is that this year’s AGBT conference on Marco Island next week doesn’t lo...

I'm committing myself this week to an uncommon intensity of posting.  It's AGBT week, and while I'm there I plan to be busy bo...

I was originally going to start this with a joke alluding to one of the signature special effects of Star Trek: The Next Generation, but giv...

As one might guess from reading this space, I always have an itch to try new sequencing technologies or updates to existing ones.  That'...

As the clear leader in the genome sequencing technology market, Illumina is often in the news.  As befitting the winter season, there's ...

This past presidential election was as nasty as any in recent memory, and so perhaps folks are reviewing their support for Churchill's d...

It's gratifying to see that yesterday's The Trouble with FASTQ item gathered a number of lively comments, and there are certainly a...

I spend a lot of time working with sequencing data, and the most common format for such data is FASTQ.  FASTQ has many things to appreciat...

Speaking of Twitter , one thing I've found it highly valuable for is discovering new tools and ideas in the bioinformatics space.  It...

For a long while, my only interaction with Twitter was to monitor key hashtags during AGBT and ASHG.  However, I've gotten myself sucked...